Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625
This examiner grants 51% of resolved cases
Jonathan Davis Mahlum serves as an examiner in Tech Center 1600 and Art Unit 1625. The examiner has handled 37 resolved cases, resulting in an allowance rate of 51.4 percent. This figure represents the outcome for applicants navigating the examination process in this specific unit, where 51.4 percent of cases reach a grant.
The interview lift of 25.6 percent highlights the impact of examiner interviews on case outcomes. Engaging in verbal discussions correlates with a change in the likelihood of allowance. This 25.6 percent lift is a key metric for developing prosecution strategies, indicating how personal advocacy relates to the 51.4 percent allowance rate for the 37 resolved cases.
The median days to allowance is 1425. This duration reflects the time required to reach a resolution in Art Unit 1625. With 37 resolved cases as the data foundation, the 51.4 percent allowance rate and 1425-day timeline offer a view of the current prosecution environment under this examiner's authority.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17920794 | Pyridine Inhibitors of Glucosylceramide Synthase and Therapeutic Methods Using the Same | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18577757 | TRIAZOLE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | Non-Final OA | BASF SE |
| 18678013 | 5,6 UNSATURATED BICYCLIC HETEROCYLES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Non-Final OA | Merck Sharp & Dohme LLC |
| 18012999 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18257261 | PI3K INHIBITORS FOR PROTECTION AGAINST GLUCOCORTICOID-INDUCED ATROPHY | Non-Final OA | Northwestern University |
| 18478684 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | Non-Final OA | The Cleveland Clinic Foundation |
| 18205745 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18010690 | SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 AGONIST AND LIPOSOMAL FORMULATIONS THEREOF | Final Rejection | The Penn State Research Foundation |
| 17599188 | METHODS AND COMPOSITIONS RELATING TO TREATMENT OF CANCER | Non-Final OA | The Penn State Research Foundation |
| 17763445 | METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE AND THALASSEMIA | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18039661 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | Final Rejection | Baylor College of Medicine |
| 18627032 | DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF | Non-Final OA | INXMED (NANJING) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy